Yugclave 625 Tablet is a combination antibiotic formulation containing Amoxycillin 500 mg and Clavulanic Acid 125 mg, designed to treat a broad spectrum of bacterial infections. Amoxycillin, a beta-lactam antibiotic, acts by inhibiting bacterial cell wall synthesis, leading to cell lysis and death. However, certain bacteria produce beta-lactamase enzymes that inactivate amoxycillin, rendering it ineffective. Clavulanic Acid, a beta-lactamase inhibitor, protects amoxycillin from enzymatic degradation, thereby extending its antibacterial activity against resistant strains. Yugclave 625 is indicated for the treatment of respiratory tract infections, urinary tract infections, skin and soft tissue infections, otitis media, sinusitis, and dental infections caused by susceptible organisms. The combination is effective against beta-lactamase producing strains of Staphylococcus aureus, Haemophilus influenzae, Escherichia coli, Klebsiella species, and other common pathogens. Dosage and duration should be determined by a healthcare professional based on the severity and type of infection. Caution is advised in patients with a history of penicillin allergy or hypersensitivity. Common adverse effects may include gastrointestinal disturbances such as diarrhea, nausea, and rash. Yugclave 625 Tablet should be used as prescribed to reduce the risk of antibiotic resistance and ensure optimal therapeutic outcomes.